Related Experiment Video
Updated: May 24, 2026

Mitochondrial Transformation in Baker's Yeast to Study Translation and Respiratory Complex Assembly
Published on: June 7, 2024
Bax345/BLyS: a novel, completely human fusion protein targeting malignant B cells and delivering a unique
Mi-Ae Lyu1, Lawrence H Cheung, Walter N Hittelman
1Department of Experimental Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, 77030, USA.
Abstract:
We generated a fusion protein Bax(345)/BLyS containing the truncated form of Bax (Bax(345)) at the N-terminus followed by a 218 linker to the B lymphocyte stimulator (BLyS). Bax(345)/BLyS was cytotoxic to a panel of diffuse large B cell lymphoma and mantle cell lymphoma lines expressing the BLyS receptors. Specific delivery of Bax(345)/BLyS to malignant B cells drove cells into apoptosis by mitochondrial dysfunction and treatment of cells with Bax(345)/BLyS induced down-regulation of Mcl-1, X-IAP, and survivin. Bax(345)/BLyS represents a new class of targeted therapeutic agents with a unique mechanism of action and may have therapeutic potential for malignant B cells.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

